SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) SVP Dragan Cicic sold 6,933 shares of the business’s stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $19.18, for a total value of $132,974.94. Following the completion of the sale, the senior vice president owned 557,361 shares in the company, valued at $10,690,183.98. This represents a 1.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
SELLAS Life Sciences Group Stock Down 8.1%
NASDAQ:SLS traded down $1.20 on Friday, reaching $13.66. 15,361,567 shares of the company’s stock were exchanged, compared to its average volume of 7,646,582. SELLAS Life Sciences Group, Inc. has a 52-week low of $1.39 and a 52-week high of $24.89. The business has a fifty day moving average of $11.11 and a 200-day moving average of $8.99.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05).
Institutional Trading of SELLAS Life Sciences Group
Several institutional investors have recently modified their holdings of SLS. Nykredit A S acquired a new position in shares of SELLAS Life Sciences Group in the 2nd quarter valued at $27,000. GAMMA Investing LLC grew its position in shares of SELLAS Life Sciences Group by 293.2% in the 3rd quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock valued at $27,000 after buying an additional 1,630 shares during the last quarter. Robinhood Markets Inc. acquired a new stake in SELLAS Life Sciences Group during the 3rd quarter worth $33,000. California State Teachers Retirement System raised its stake in SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after acquiring an additional 1,709 shares in the last quarter. Finally, Wealthfront Advisers LLC acquired a new stake in SELLAS Life Sciences Group during the 1st quarter worth $48,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have commented on SLS shares. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, SELLAS Life Sciences Group currently has a consensus rating of “Hold” and an average target price of $10.00.
Read Our Latest Research Report on SELLAS Life Sciences Group
Recent SELLAS Life Sciences Group Headlines
These are some of the SLS headlines that stood out recently:
- Positive Sentiment: SELLAS expects to raise about $150 million in gross proceeds from the sale of 11.54 million shares at $13 each. The funds could support development of its GPS and SLS009 cancer candidates. Underwriters also have an option to buy up to 1.73 million additional shares. SELLAS offering announcement
- Neutral Sentiment: A Seeking Alpha article upgraded its rating after describing a “big win,” while noting areas of uncertainty. The headline provided does not specify the underlying development, limiting what can be concluded about its likely effect on the shares. Seeking Alpha article
- Neutral Sentiment: A report says a recent filing has prompted speculation among retail investors that SELLAS may have greater buyout leverage. That is an investor interpretation, not a confirmed acquisition process or offer. MSN report on the offering and buyout speculation
About SELLAS Life Sciences Group
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
Featured Articles
- Five stocks we like better than SELLAS Life Sciences Group
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
